Recipharm Sustainability Profile
Recipharm AB, a leading contract development and manufacturing organisation (CDMO), is headquartered in Sweden (SE) and operates extensively across Europe, North America, and Asia. Founded in 1995, Recipharm has established itself as a key player in the pharmaceutical industry, specialising in the development and production of complex drug formulations, including sterile and non-sterile products. The company offers a diverse range of services, from drug development and manufacturing to packaging and analytical services, catering to both small biotech firms and large pharmaceutical companies. Recipharm's commitment to quality and innovation has earned it a strong market position, with notable achievements in expanding its global footprint and enhancing its technological capabilities. With a focus on sustainability and efficiency, Recipharm continues to set benchmarks in the CDMO sector, making it a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does Recipharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recipharm's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recipharm's reported carbon emissions
In 2024, Recipharm reported total carbon emissions of approximately 22773000 kg CO2e for Scope 1, 1600000 kg CO2e for Scope 2, and 183618000 kg CO2e for Scope 3. This reflects a slight decrease in Scope 1 emissions from 24216000 kg CO2e in 2023, while Scope 2 emissions also decreased from 3193000 kg CO2e. However, Scope 3 emissions increased from 179203000 kg CO2e in 2023. Recipharm has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42.1% by 2030 from a 2021 baseline. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions by 2030, which encompasses emissions from purchased goods and services, upstream transportation, and waste generated in operations. These targets have been validated by the Science Based Targets initiative (SBTi). Furthermore, Recipharm is committed to achieving net-zero carbon emissions by 2050, with interim goals of reducing Scope 1 and 2 emissions to near zero by the mid-2020s. The company also plans to increase its sourcing of renewable electricity from 93.5% in 2021 to 100% by 2030. Overall, Recipharm's emissions data and climate commitments reflect a proactive approach to sustainability within the pharmaceutical sector, aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,442,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,517,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 463,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Recipharm's Industry?
How Carbon Intensive is Recipharm's Location?
Recipharm's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Recipharm has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Vetter Pharma
Frequently Asked Questions
Common questions about Recipharm's sustainability data and climate commitments